Ask about this productRelated genes to: NUB1 antibody
- Gene:
- NUB1 NIH gene
- Name:
- negative regulator of ubiquitin like proteins 1
- Previous symbol:
- -
- Synonyms:
- BS4, NYREN18, NUB1L
- Chromosome:
- 7q36.1
- Locus Type:
- gene with protein product
- Date approved:
- 2006-07-27
- Date modifiied:
- 2016-10-05
Related products to: NUB1 antibody
Related articles to: NUB1 antibody
- NEDD8 ultimate buster 1 is an interferon-inducible tumor suppressor increasingly recognized as a prognostic biomarker in breast cancer. Low cytoplasmic expression correlates with aggressive disease, yet little is known about its dynamics between primary and metastatic estrogen-receptor-negative tumors. - Source: PubMed
Publication date: 2026/03/22
Arshad MariaAbdullah Amira RaudhahIsmail FuadYahaya AzyaniTan Geok-ChinChia Suet LinSalleh Md Salzihan MdPezzella FrancescoTan Ka-Liong - Neddylation is a post-translational modification suppressed by the endogenous inhibitor NUB1, and its dysregulation in rheumatoid arthritis (RA) promotes inflammation and NF-κB activation. NUB1 expression in RA and osteoarthritis (OA) synovium and mechanisms underlying defective NUB1 induction in RA fibroblast-like synoviocytes (FLS) were evaluated. NEDD8 and IL-6 protein expression was increased and NUB1 was reduced in RA synovium compared with OA tissue, with significant differences in the lining region that correlated with higher cytokine expression and NF-kB translocation. IL-1β–induced NUB1 induction was impaired in RA FLS at both the mRNA and protein levels. To evaluate the mechanism, we assessed mRNA stability using actinomycin D, examined the role of SNHG12 by siRNA knockdown, analyzed MAP kinase signaling, and measured NUB1 promoter activity with a luciferase reporter assay. None could explain the reduced induction observed in RA FLS. Treatment with the DNA methylation inhibitor 5-azacytidine and the histone methylation inhibitor EPZ6438 partially reversed the difference in NUB1 induction, whereas the histone deacetylase inhibitors ITF2375 and MS275 eliminated it. Therefore, defective NUB1 induction in RA FLS is related to the aberrant epigenetic landscape in RA FLS and is associated with increased neddylation and increased IL-6 expression in rheumatoid synovium. Overcoming increased neddylation in RA represents a novel therapeutic approach. - Source: PubMed
Publication date: 2026/02/10
Ono YosukeMachado Camilla R LChoi EuniceBoyle David LWang WeiFirestein Gary S - - Source: PubMed
Publication date: 2025/08/04
- NEDD8 Ultimate Buster 1 (NUB1) is a regulator of the cell cycle and a prognostic marker in cancer patients. However, its role in breast cancer (BC) and its response to 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) treatment remain unclear. This study investigated NUB1's predictive value in FEC treatment and its mechanistic interaction with the oestrogen receptor (ER) in BC. MDA-MB-231 and MCF-7 cells were treated with FEC and analysed via flow cytometry for cell cycle distribution. Western blotting assessed NUB1 and ERα expression, while immunohistochemistry was conducted on a retrospective cohort ( = 85) from Malaysian hospitals to evaluate the clinical significance of NUB1 expression. FEC treatment induced S and G2 phase cell cycle arrest in MDA-MB-231 cells ( = 0.04 and = 0.02, respectively), accompanied by NUB1 upregulation. In MCF-7 cells, G2/M arrest was observed ( = 0.01), with reduced ERα expression and increased NUB1 levels in both cell lines. Lower cytoplasmic NUB1 expression was associated with poorer overall survival (OS) (HR = 0.60; 95% CI = 0.32-1.11; = 0.10). Patients with low NUB1 and low ER expression showed the worst OS outcomes. NUB1 upregulation following FEC treatment led to cell cycle arrest in ER-negative cells, whereas ERα suppression failed to induce S-phase arrest in ER-positive cells. Low NUB1 expression predicted poorer OS and increased BC recurrence. By integrating in vitro and clinical data, this study suggests that NUB1 may serve as a predictive biomarker in FEC-treated breast cancer. Larger studies are needed to validate and establish NUB1's predictive role in FEC-treated patients. - Source: PubMed
Publication date: 2025/05/27
Arshad MariaAbdullah Amira RaudhahIsmail FuadPezzella FrancescoYahaya AzyaniTan Geok-ChinChia Suet LinMd Salleh Md SalzihanAbdullah NoraidatulakmaTan Ka-Liong - - Source: PubMed
Publication date: 2025/03/16
Tan Ka-LiongHaider SyedZois Christos EHu JiantingTurley HelenLeek RussellBuffa FrancescaAcuto OresteHarris Adrian LPezzella Francesco